Executive Summary
HHS/BARDA dominates with two $100M+ cost-plus-fixed-fee contracts fueling small biotech R&D in biothreat countermeasures (Marburg immunotherapy, anti-infectives), providing multi-year funding visibility to 2030-2036 and partial outlays exceeding $98M combined. Contrast with a stale $175M CMS data processing contract (ended 2020, $0 outlayed), signaling execution gaps in legacy services. Investors should prioritize BARDA biodefense exposure over dormant CMS IT.
Tracking the trend? Catch up on the prior All HHS Contracts digest from February 22, 2026.
Investment Signals(2)
- BARDA long-term biotech R&D funding(HIGH)▲
Two small biotechs secured $209M total obligations (45-48% outlayed) for infectious disease programs via full/open competition, with options up to $397M and runways to 2036.
- Inactive CMS data services legacy(HIGH)▲
$175M obligation fully optioned but $0 outlayed post-2020 end-date, indicating no active funding flow.
Risk Flags(2)
- Execution[HIGH RISK]▼
Outlays lag obligations: 0% (QLARANT), 48% (MAPP), 45% (Medicines), with long periods to 2030-2036 vulnerable to delays.
- Market[MEDIUM RISK]▼
BARDA R&D dependence on funding continuity amid cost-sharing (Medicines) and partial obligations ($111M vs $299M potential for MAPP).
Opportunities(2)
- ◆
$188M remaining potential outlays ($54M MAPP options to $299M, $54M Medicines to full $98M) plus extensions to 2036.
- ◆
Follow-on potential for CMS data processing given QLARANT's history, despite current dormancy.
Sector Themes(2)
- ◆
Small biotechs winning full competition awards for long-duration (14+ years) infectious disease programs, with $209M obligated.
- ◆
Expired CMS contracts show $0 execution despite high obligations, diverging from active biotech funding.
Watch List(3)
- 👁
{"entity"=>"MAPP Biopharmaceutical", "reason"=>"$111M obligated (potential $299M) for Marburg program with 48% outlayed", "trigger"=>"Option exercises pushing toward 2036 end-date"}
- 👁
{"entity"=>"The Medicines Company", "reason"=>"$98M full-value anti-infectives portfolio to 2030, 45% outlayed", "trigger"=>"Remaining $54M outlay acceleration or cost-sharing matches"}
- 👁
{"entity"=>"BARDA biotech pipeline", "reason"=>"Concentration in biothreat R&D signals sector momentum", "trigger"=>"New awards in NAICS 541711/541714"}
Get daily alerts with 2 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 3 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC